<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>Spring Builders: 340B Orphan Drug Solutions</title>
    <description>The latest articles on Spring Builders by 340B Orphan Drug Solutions (@340b_orphandrugsolution).</description>
    <link>https://springbuilders.dev/340b_orphandrugsolution</link>
    <image>
      <url>https://springbuilders.dev/images/3BVCBCwLHFG0E6boizWoKBcsn8nUeoz_bU-ccr2h_b8/rs:fill:90:90/g:sm/mb:500000/ar:1/aHR0cHM6Ly9zcHJp/bmdidWlsZGVycy5k/ZXYvdXBsb2Fkcy91/c2VyL3Byb2ZpbGVf/aW1hZ2UvOTI3Ny8w/ZTUwNzQwNi0wZTlm/LTRhZjktYmQ2Yy1k/OTU2ZWMzMTJjYWIu/cG5n</url>
      <title>Spring Builders: 340B Orphan Drug Solutions</title>
      <link>https://springbuilders.dev/340b_orphandrugsolution</link>
    </image>
    <atom:link rel="self" type="application/rss+xml" href="https://springbuilders.dev/feed/340b_orphandrugsolution"/>
    <language>en</language>
    <item>
      <title>Beyond the Drug Price: How Hospitals Can Identify Overlooked Orphan Drug Savings Opportunities</title>
      <dc:creator>340B Orphan Drug Solutions</dc:creator>
      <pubDate>Tue, 17 Nov 2026 11:34:40 +0000</pubDate>
      <link>https://springbuilders.dev/340b_orphandrugsolution/beyond-the-drug-price-how-hospitals-can-identify-overlooked-orphan-drug-savings-opportunities-5h5n</link>
      <guid>https://springbuilders.dev/340b_orphandrugsolution/beyond-the-drug-price-how-hospitals-can-identify-overlooked-orphan-drug-savings-opportunities-5h5n</guid>
      <description>&lt;p&gt;&lt;a href="https://springbuilders.dev/images/b9PA6Nt_VRO_MVV6wzoFh0onySJr7CL80WYtZG74bks/rt:fit/w:800/g:sm/q:0/mb:500000/ar:1/aHR0cHM6Ly9zcHJp/bmdidWlsZGVycy5k/ZXYvdXBsb2Fkcy9h/cnRpY2xlcy9oMWxz/d2dodWw1cnpvbGRi/ODF5ay5qcGc" class="article-body-image-wrapper"&gt;&lt;img src="https://springbuilders.dev/images/b9PA6Nt_VRO_MVV6wzoFh0onySJr7CL80WYtZG74bks/rt:fit/w:800/g:sm/q:0/mb:500000/ar:1/aHR0cHM6Ly9zcHJp/bmdidWlsZGVycy5k/ZXYvdXBsb2Fkcy9h/cnRpY2xlcy9oMWxz/d2dodWw1cnpvbGRi/ODF5ay5qcGc" alt="Image description" width="800" height="433"&gt;&lt;/a&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Hospital pharmacy budgets face a difficult balancing act. Healthcare organizations must provide access to essential medications while managing rising acquisition costs, reimbursement pressures, and compliance responsibilities. Specialty medications and treatments for rare diseases can make this challenge even more complex.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Yet some opportunities for &lt;a href="https://340borphandrugsolutions.com/orphan-drug"&gt;orphan drug savings&lt;/a&gt;&lt;/span&gt;&lt;span&gt; begin with a question that hospitals do not always investigate thoroughly: Are we paying the right price for every eligible medication, and are our purchasing decisions aligned with current 340B requirements?&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Answering this question requires more than reviewing invoices. Hospitals need a structured approach to drug classification, purchasing data, and regulatory compliance. A closer look at these areas can reveal potential savings opportunities without compromising patient care or program integrity.&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;Why Orphan Drug Classification Matters to Hospital Budgets&lt;/strong&gt;&lt;/h3&gt;

&lt;p&gt;&lt;span&gt;Orphan drug designation is granted by the U.S. Food and Drug Administration (FDA) to drugs and biological products intended to prevent, diagnose, or treat rare diseases or conditions. The designation can provide sponsors with incentives that support the development of treatments for smaller patient populations.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;The FDA outlines these incentives, which include potential tax credits for qualified clinical trials, exemption from certain user fees, and potentially seven years of market exclusivity following approval.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Source:&lt;/span&gt;&lt;a href="https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products"&gt; &lt;span&gt;FDA guidance on orphan product designation&lt;/span&gt;&lt;/a&gt;&lt;span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;For hospitals, however, an orphan designation does not automatically determine whether a medication qualifies for a 340B discount. The hospital's covered entity category and the applicable statutory requirements also matter.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;This distinction is important because incorrect assumptions can lead to two costly outcomes. A hospital may overlook a legitimate discount opportunity, or it may claim a discount that is not permitted under the applicable rules.&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;Understanding the Orphan Drug Exclusion Under 340B&lt;/strong&gt;&lt;/h3&gt;

&lt;p&gt;&lt;span&gt;The 340B Drug Pricing Program allows eligible healthcare organizations to purchase covered outpatient drugs at discounted prices. The program is intended to help eligible providers stretch limited resources and serve more patients.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;However, federal law establishes an orphan drug exclusion for four hospital categories: critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;According to the&lt;/span&gt;&lt;a href="https://www.hrsa.gov/opa/program-requirements/orphan-drug-exclusion"&gt; &lt;span&gt;Health Resources and Services Administration (HRSA)&lt;/span&gt;&lt;/a&gt;&lt;span&gt;, manufacturers are not required to provide 340B discounts on qualifying orphan drugs to these entities. Manufacturers may voluntarily offer discounts.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;The exclusion makes accurate classification essential. Hospitals should not assume that every orphan-designated medication is excluded for every covered entity. Nor should they assume that all purchases involving an affected hospital are automatically eligible for discounted pricing.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;The relevant requirements must be evaluated against the organization's registered category and the medication's designation and use, with appropriate attention to applicable legal interpretations and manufacturer policies.&lt;/span&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;Four Practical Ways to Find Orphan Drug Savings Opportunities&lt;/strong&gt;&lt;/h2&gt;

&lt;h3&gt;&lt;strong&gt;1. Review Purchasing Data for High-Cost Medications&lt;/strong&gt;&lt;/h3&gt;

&lt;p&gt;&lt;span&gt;Start by identifying medications that contribute significantly to outpatient pharmacy expenditure. Analyze acquisition costs, purchasing volumes, dispensing patterns, and available pricing information.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Rather than focusing exclusively on the highest-priced products, examine recurring purchases that create substantial annual expenditure. A relatively small pricing difference on a frequently purchased medication may produce meaningful savings over time.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Compare these findings with the organization's current purchasing and compliance records. This creates a clearer picture of where additional investigation could deliver the greatest financial benefit.&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;2. Verify Orphan Designation Against Reliable Sources&lt;/strong&gt;&lt;/h3&gt;

&lt;p&gt;&lt;span&gt;Drug designation information can change, and a medication's status should not be determined solely by a supplier's product description or an outdated internal spreadsheet.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;The FDA maintains an&lt;/span&gt;&lt;a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/"&gt; &lt;span&gt;Orphan Drug Designations and Approvals database&lt;/span&gt;&lt;/a&gt;&lt;span&gt;. HRSA also directs 340B stakeholders to the FDA database when assessing orphan drug status.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Hospitals can establish a documented review process that records the product, designation status, relevant indication, verification date, and applicable purchasing restrictions.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;This step supports &lt;/span&gt;&lt;strong&gt;340B orphan drug compliance&lt;/strong&gt;&lt;span&gt; while helping pharmacy and finance teams distinguish products that require further review from those that may qualify for discounts.&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;3. Investigate Manufacturer Discount Availability&lt;/strong&gt;&lt;/h3&gt;

&lt;p&gt;&lt;span&gt;The absence of a mandatory discount does not necessarily mean that a discount is unavailable. HRSA explicitly states that manufacturers may voluntarily offer discounts on orphan drugs to hospitals affected by the exclusion.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Hospitals should therefore verify current manufacturer terms rather than treating the exclusion as an automatic end to the pricing review.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Document manufacturer communications, applicable product conditions, and any approved discount arrangements. Purchasing teams should also confirm that negotiated terms are consistent with program requirements and internal policies.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;These checks can uncover legitimate &lt;/span&gt;&lt;strong&gt;hospital drug cost savings&lt;/strong&gt;&lt;span&gt; while reducing reliance on assumptions about product eligibility.&lt;/span&gt;&lt;/p&gt;

&lt;h3&gt;&lt;strong&gt;4. Connect Pharmacy, Finance, and Compliance Teams&lt;/strong&gt;&lt;/h3&gt;

&lt;p&gt;&lt;span&gt;Drug purchasing decisions often involve multiple departments. Pharmacy teams understand medication use, procurement teams manage supplier relationships, finance teams analyze expenditure, and compliance professionals interpret program requirements.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;When these functions operate separately, an important pricing detail can be missed.&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;A shared review process can bring together acquisition data, product designation records, manufacturer terms, and documented eligibility decisions. Assigning responsibility for periodic reviews also helps hospitals respond when purchasing arrangements or relevant regulatory information changes.&lt;/span&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;Measure Savings Without Increasing Compliance Risk&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;&lt;span&gt;A successful savings initiative needs measurable outcomes. Hospitals should establish a baseline before implementing changes and track the financial impact of verified pricing improvements.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Useful measures include:&lt;/span&gt;&lt;/p&gt;

&lt;ul&gt;
&lt;li&gt;&lt;span&gt;Annual expenditure on selected orphan-designated medications.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Differences between existing acquisition costs and verified alternative pricing.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Confirmed discounts obtained through eligible purchasing arrangements.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Staff time required to review product status and maintain supporting documentation.&lt;/span&gt;&lt;/li&gt;
&lt;li&gt;&lt;span&gt;Compliance exceptions identified and corrected during periodic reviews.&lt;/span&gt;&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;span&gt;Hospitals should distinguish realized savings from estimated opportunities. A potential discount should not be reported as a financial gain until the purchasing terms have been confirmed and the savings can be substantiated.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;HRSA's&lt;/span&gt;&lt;a href="https://www.hrsa.gov/opa/program-requirements"&gt; &lt;span&gt;340B program requirements&lt;/span&gt;&lt;/a&gt;&lt;span&gt; emphasize accurate records, prevention of diversion to ineligible patients, prevention of duplicate discounts, and audit readiness. A savings strategy should incorporate these safeguards from the beginning.&lt;/span&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;When Orphan Drug Consulting Can Help&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;&lt;span&gt;Some organizations have limited internal capacity to evaluate complex medication classifications, purchasing records, and manufacturer arrangements. In these situations, &lt;/span&gt;&lt;strong&gt;orphan drug consulting&lt;/strong&gt;&lt;span&gt; can help structure the review process and identify areas that warrant closer examination.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;A useful assessment may include a review of purchasing data, verification of orphan drug designations, evaluation of applicable exclusion requirements, and recommendations for stronger documentation and ongoing monitoring.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;The objective is not to pursue every apparent discount. It is to identify legitimate opportunities, prioritize the most promising findings, and create a repeatable process that supports both financial performance and compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;Hospitals should also ensure that any proposed purchasing changes receive appropriate internal and legal review where necessary.&lt;/span&gt;&lt;/p&gt;

&lt;h2&gt;&lt;strong&gt;Turn Regulatory Complexity Into Better Purchasing Decisions&lt;/strong&gt;&lt;/h2&gt;

&lt;p&gt;&lt;span&gt;Orphan drug pricing deserves more than a one-time review. As medication portfolios, purchasing volumes, and manufacturer arrangements evolve, hospitals benefit from a consistent process for identifying savings opportunities and validating eligibility.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;By combining reliable designation data, careful purchasing analysis, manufacturer communication, and cross-functional oversight, healthcare organizations can make more informed decisions about&lt;/span&gt;&lt;strong&gt; orphan drug savings.&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;For hospitals seeking a more structured approach,&lt;/span&gt;&lt;a href="https://340borphandrugsolutions.com/"&gt; &lt;span&gt;340B Orphan Drug Solutions&lt;/span&gt;&lt;/a&gt;&lt;span&gt; offers a starting point for exploring orphan drug exclusion, compliance, and savings-related resources.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span&gt;The goal is straightforward: make every eligible purchasing decision count while protecting the integrity of the 340B program and maintaining the focus on patient care.&lt;/span&gt;&lt;/p&gt;

</description>
    </item>
  </channel>
</rss>
